Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
Study Details
Study Description
Brief Summary
Vienna Consensus has identified 10% damage rate after ICSI as a competency value. Despite the highest quality embryologists doing ICSI, degeneration sometimes occurs due to oocyte factors such as the fragile membrane, etc. Latrunculin A serves to facilitate spindle or pronuclear transfer procedures helping to reduce the damage rate with no harm reported. Using Latrunculin A during ICSI could serve to rescue some oocytes from the degeneration allowing for more chances of viable zygotes,
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Handling Medium Supplemented with Latrunculin A
|
Other: Medium Supplemented with Latrunculin A
A medium with in-house supplementation of Latrunculin A to decrease oocyte degeneration after ICSI and improve the survival rate
|
No Intervention: Handling Medium as it is.
|
Outcome Measures
Primary Outcome Measures
- oocyte survival rate [6 days of culture]
Secondary Outcome Measures
- fertilization rate [6 days of culture]
- Blastocyst formation rate [6 days of culture]
- Blastocyst quality rate [6 days of culture]
- Clinical pregnancy rate [three months]
- Implantation rate [7 weeks]
- Ongoing pregnancy rate [12 weeks]
Eligibility Criteria
Criteria
Inclusion Criteria:
- ICSI participants
Exclusion Criteria:
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Banon Assiut | Assiut | Egypt | ||
2 | IbnSina IVF Center | Sohag | Egypt |
Sponsors and Collaborators
- Ibn Sina Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IbnSinaIVF-ICSI-LA